falnidamol
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00003980)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1- Mol. weight
- 387.85 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL258940 ↗
Also known as
- bibx 1382
- bibx 1382
- bibx-1382
- bibx-1382
- falnidamol
- falnidamol
- falnidamol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003980 | Phase 1 | Feb 1, 1999 | European Organisation for Research and Treatment of Cancer, Kaiser Franz Josef Hospital |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Kaiser Franz Josef Hospital | Academic/Hospital | 1 | 0 | 1 | 1999 |
2 organizations
Page 1 / 1